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Abstract
In 1999, the Global Advisory Committee on Vaccine Safety (GACVS) was established by the 
World Health Organization (WHO) to provide independent scientific advice on issues relating to 
the safety of vaccines and immunization. Fifteen years onward, we conducted a multi-faceted 
review to evaluate the impact, reach and challenges facing GACVS, including the role GACVS 
plays in informing global, regional and WHO member state vaccine policy. The methods included 
measures of organizational structure, citation impact, themes approached, and a discussion by 
previous and current members to evaluate past, present and future challenges. Given the increasing 
range of data sources and the deployment of many new vaccines, the Committee is facing the 
complex task of identifying the best available evidence for recommendations on vaccine safety. To 
help meet the increased demand for public transparency in decision making, GACVS-structured 
methodology for evidence-based decisions is evolving. GACVS also promotes best practices and 
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capacity building for timely and accurate risk assessment; risk communications; outreach to help 
countries maintain and, if needed, rebuild public trust in vaccines; and advocacy for bridging the 
major gaps in vaccine safety capacity globally.
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1. Introduction
Since vaccines are usually administered to healthy individuals to prevent their target 
vaccine-preventable diseases (VPD), they are typically held to a higher standard of safety 
than medicinal products used to treat ill patients. To identify common and less common (but 
not rare) problems at the preapproval stage, vaccines undergo extensive safety and efficacy 
studies needed to fulfill stringent regulatory licensure requirements [1,2]. Due to the limited 
size and scope of pre-licensure safety studies, however, post licensure monitoring and 
evaluation is needed and increasingly performed to identify rare safety concerns. For two 
centuries, vaccines have demonstrated their public health value in preventing and controlling 
infectious diseases that previously injured or killed millions of individuals globally each 
year. However, these successes in controlling and in some cases eliminating their target VPD 
have paradoxically resulted in increased concerns about the safety of vaccines in recent 
decades [3]. Occasionally, rare serious adverse vaccine reactions occurring less frequent than 
one in 10,000 doses may become evident after a new vaccine is in widespread use in the 
general population [4–6]. But more commonly, as vaccine coverage reach high enough level 
to decrease the threat of VPDs, there is also a concomitant increase in coincidental adverse 
event following immunization (AEFI). Due to “post hoc ergo propter hoc”, a common public 
misunderstandings about logic, these AEFIs may be falsely attributed as being caused by 
immunization. This misattribution seems particularly common for medical conditions whose 
etiology and pathophysiology are incompletely understood (e.g. autism, and multiple 
sclerosis). As information sharing via internet becomes all too easy, however, so is the 
propagation of such errors [7].
In the absence of adequate capacity to confirm or reject such AEFI's being caused by 
vaccination in a timely manner, loss of public confidence in a vaccine may occur 
(manifested as either hesitancy or refusal resulting in reduced coverage), with consequent 
return of outbreaks of VPDs [8,9]. Enhanced surveillance coupled with sound epidemiologic 
studies for vaccine safety from the local to the global levels helps provide the best evidence 
for decision making by parents, patients, providers, policy makers and society. This is a 
challenging capacity building process, especially in low and middle income countries 
(LMIC) where AEFI surveillance, investigation and management are often not well 
established. This process requires long-term commitment and significant resources to create 
the required safety monitoring infrastructure. The Global Advisory Committee on Vaccine 
Safety (GACVS) was established by the World Health Organization (WHO) in 1999 due to 
the growing need for independent review of the (often limited) available evidence and to 
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provide recommendations on emerging vaccine safety issues globally, but especially for 
LMICs lacking such capacity [10–13]. This paper presents an analysis and review of the 
work and impact of GACVS over its 15 years of existence with suggestions for further 
improvements.
2. Methods
The review of GACVS's contributions and challenges was undertaken at the Center for 
Global Health, University of Colorado Denver, USA along with discussions by a panel of 
experts who were current or previous members of the GACVS. The WHO GACVS 
Secretariat provided support and assistance with access to archival documentation. The 
review encompassed: (a) an organizational evaluation of GACVS to define its composition, 
expertise, geographical representativeness; (b) an assessment of the GACVS's activities 
through a quantitative review of its reports, and an estimation of their impact on their global, 
regional and country target audiences; and finally, (c) a regulator evaluation survey. The 
GACVS composition, membership history, geography and professional backgrounds were 
obtained from a previous independent review of WHO immunization advisory committees 
and the list of current and past members available at the WHO website [14,15].
Given that direct assessment of GACVS's impact on the science of vaccine safety or on the 
shaping of local, regional and global vaccine policy was difficult, an indirect measure, the 
citation factor through Google Scholar Impact, was used. To undertake this, all GACVS 
meeting reports accessible on its website (from 1999 until 2014) as well as other GACVS 
and WHO publications in the scientific literature and related reports and guidelines were 
evaluated for thematic content, type of recommendation and impact generated in the 
published literature. The keywords “gacvs” and “Global Advisory Committee on Vaccine 
Safety” were used and the relevant publications ranking, number of references linked and 
their relevance to other scholarly literature was obtained. Whereas most academic databases 
and search engines allow users to select one factor (e.g. relevance, citation counts, or 
publication date) to rank results, Google Scholar grades them using a combined algorithm. 
For all topics reviewed by GACVS, the date of the Committee review was noted and the 
number of recommendations and conclusions per year recorded. For every GACVS 
conclusion, we classified the action as: (a) review of the evidence, (b) recommendation of a 
policy modification, or (c) request for additional research or evidence. The WHO vaccine 
position papers were also evaluated to determine if GACVS recommendations had been 
incorporated and cited as part of the review [16].
As there is no formal process to gauge the visibility and consumer use of GACVS 
recommendations beyond WHO, we designed a nine item qualitative survey. It was 
administered in a confidential manner to a convenience sample of drug regulatory experts 
from all six WHO regions who were attending a forum for drug regulation (International 
Conference of Drug Regulatory Authorities – ICDRA – August 27–29, 2014). Participants 
were asked about their knowledge of GACVS as well as the WHO's Weekly 
Epidemiological Record (WER), and the importance of GACVS recommendations in their 
regulatory work on vaccines.
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Finally, to help identify the challenges and opportunities faced by GACVS, we held a 
discussion amongst previous and current members at the June 2014 GACVS meeting [17]. 
Presentations on past work of GACVS and results from the organizational and impact 
evaluation were used to stimulate discussion. These discussions were recorded, transcribed 
and themes related to contributions to the vision and future work of GACVS were noted.
3. Results
3.1. GACVS organizational assessment
GACVS has been an independent scientific advisory group to WHO, responsible for 
providing: (a) technical advice on vaccine safety; (b) assessment of risks related to vaccines 
in order to assist policy-makers in balancing benefits and risks as part of evidence-based 
policies; and (c) guidance on the development of vaccine safety systems, strategies and 
mechanisms to strengthen vaccine safety at the national and global levels [18].
GACVS is composed of experts from around the world in the fields of vaccine safety, 
vaccinology and allied sciences such as epidemiology, biostatistics, pharmacovigilance, 
biologic product regulation and clinical medical sciences. The committee's ~15 members are 
selected by an open application process organized by the WHO secretariat. Members serve 
on the Committee for three years with possible renewal for a second term. Over the past 15 
years, GACVS has had 41 members from 20 different countries, representing all WHO 
regions, although 26 (63.4%) originate from high-income countries in Europe, North 
America and Australia as vaccine safety expertise is highly technical (Fig. 1).
GACVS members participate in bi-annual in-person meetings; they also work in topic 
specific sub-groups to develop statements (e.g. vaccines and HIV, vaccines in pregnancy, 
etc.). The Committee also meets as needed by teleconference in response to new or 
emerging issues. For example, in early 2010, academic investigators reported finding that 
one manufacturer's rotavirus vaccine contained DNA from porcine circovirus type 1 [19]. 
The committee met by teleconference on March 25, 2010, and posted a statement on line the 
following day [20].
The GACVS agenda is determined by its current and former members, together with the 
WHO secretariat (who incorporates the needs of the Strategic Advisory Group of Experts 
(SAGE), WHO's principal advisory group for vaccines and immunizations [21]). National 
immunization programs and WHO Regional Offices may also bring forward safety issues 
for consideration. Invited experts and observers may contribute in providing the Committee 
with up to date specific information but decisions or recommendations are, as a rule, taken 
by consensus and involve only committee members, not WHO staff or the invited observers 
or experts.
3.2. Contributions of GACVS to Vaccine Safety Policy
Information on “vaccine safety” issues has increased exponentially in the past 50 years (Fig. 
2) – From ≤10 publications per year in the 1960s to >10,000 per year in the past decade. 
Furthermore, the proportion of publications in Medline related to “vaccine safety” compared 
to all “vaccine” topics has increased from <1% to 8.3% in 2013. Since its formation, 
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GACVS has been challenged to summarize, analyze and translate the available evidence of 
vaccine safety. Typically, this evidence can be obtained from (a) clinical trials conducted 
before regulatory approval for indicated uses; and (b) estimated incidence of AEFI 
attributable to a vaccine obtained from post-licensure surveillance and other studies. The 
GACVS uses this evidence to make recommendations that inform public policy and respond 
transparently to global vaccine safety concerns. At the time of the review, GACVS had 
produced 106 reports that recap the discussions and determinations of the Committee 
addressing topics related to vaccine safety and risk assessment of vaccine products (Table 1). 
Since 2001, GACVS reviews and resolutions have been published in the WER within 2 
months following its biannual meetings in June and December. Reports from additional ad 
hoc meetings by teleconference are also posted on the GACVS website within a few days of 
the meeting. Table 1 also maps how GACVS followed up on many topics until a policy 
recommendation could be issued.
GACVS has also released 21 vaccine safety statements on 10 topics considered to be 
priorities by member countries or the WHO secretariat [14]. GACVS's conclusions also 
provide the safety elements of the WHO position papers [16], although not cited as such. 
GACVS risk assessments and resolutions are regularly presented to SAGE, the Expert 
Committee on Biological Standards (ECBS), and regional technical advisory groups related 
to immunization.
In May 2014, at the time of the review of GACVS reports and articles, Google Scholar 
contained ~160 million documents. Google Scholar Impact of the 21 vaccine statements and 
106 WER GACVS reports found the most cited GACVS meeting report was that from 
December 2005 with 52 citations (Fig. 3). In that meeting, GACVS had reviewed the safety 
of Rotashield® vaccine, the potential safety of pandemic influenza vaccination and the safety 
of adjuvants. The second most cited meeting report, from June 2002, provided an evaluation 
of the safety of thiomersal-containing vaccines as well as the risk of multiple sclerosis and 
leukemia after hepatitis B vaccine. The third and fourth most commonly cited meeting 
reports included discussions on the issues of thiomersal, Japanese encephalitis vaccine 
safety, hexavalent vaccine safety, safety of novel influenza vaccines and age of 
administration and safety of rotavirus vaccine.
3.3. Example of a GACVS recommendation on policy globally, then nationally
At the June 2003 meeting, GACVS noted the repeated reports of local and disseminated 
BCG infection occurring after BCG immunization in persons with HIV and called for closer 
monitoring of this event [22–25]. In November of 2007, following new evidence from 
Argentina and South Africa, GACVS concluded that a higher risk of disseminated BCG 
disease was present in HIV-infected infants and BCG vaccine should not be used in children 
who are known to be HIV infected; BCG should continue to be provided at birth, however, 
to infants regardless of HIV exposure in TB highly endemic countries where no early HIV 
infection confirmation was possible. This recommendation, reviewed again in 2009, allowed 
many middle-income countries in which HIV early diagnosis is available to prevent such 
adverse events and stimulated the development of new guidelines for highly endemic 
countries [26].
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3.4. GACVS contributions to vaccine safety methods and systems
During the past 15 years, GACVS has actively contributed to the development of vaccine 
safety tools, methods and strategies [27–29], frequently bringing together representatives of 
countries and regions to ensure broad participation. In partnership with the Uppsala Drug 
Monitoring Center, GACVS promoted a new classification of AEFI, its core data elements 
and indicators that can be used in country and regional surveillance systems [30]. As result 
of a WHO and Bill and Melinda Gates Foundation project on the development of a global 
network for vaccine safety monitoring, GACVS also endorsed the revision of the AEFI 
causality assessment algorithms [31], vaccine specific safety information documents [32], 
and facilitated the development of on-line vaccine safety learning modules [33]. The 
causality assessment algorithm was further revised following input from low and middle 
income country users [34,35]. These revised tools are available to all countries and are 
disseminated by WHO through regional workshops and in country meetings. GACVS also 
reviewed and advised WHO on two key documents: (1) the Global Vaccine Safety Blueprint 
– WHO's strategy to optimize the safety of vaccines through effective use of 
pharmacovigilance principles and methods in all countries; and (2) the Global Vaccine 
Action Plan (GVAP), targeting LMICs to implement practices and tools to allow more 
systematic and useful vaccine safety information [36,37].
3.5. GACVS outreach and communication
GACVS has continuously expanded its mechanisms for communication of its 
recommendations to WHO technical audiences using WHO's WER, the GACVS website 
and through SAGE meetings and its conclusions. The GACVS audiences include national 
governments and international organizations that deal with policies regarding vaccine safety, 
professional organizations and immunization technical advisory groups especially those 
from LMIC. One GACVS initiative to reach out to broader audiences and help counteract 
misinformation about vaccines was the creation of the Vaccine Safety Net (VSN) launched 
in 2003 [38]. Through a series of quality indicators developed by GACVS, VSN provides a 
clearinghouse, a listing of websites that feature scientifically sound and transparent vaccine 
safety information [39].
The convenience survey of national drug regulatory experts attending ICDRA in 2014 
resulted in 75 questionnaire responses from all WHO Regions with 46 (61%) reporting that 
they knew of GACVS's work, 19 (25%) used its recommendations, but 49 (65%) had never 
received or read WER. Not receiving or reading WER was associated with not knowing 
about GACVS (47% vs. 89%), nor using its recommendations (11% vs. 90%). The majority 
of participants considered GACVS recommendations for their work as regulators as very 
important (64%) or somewhat important (25%).
3.6. GACVS challenges
The 2-h discussion amongst GACVS members in 2014 involved 6 past and 12 current 
members. GACVS's work was considered well established and well recognized, with 
comments made about its value and importance especially to low and middle income 
countries who do not have significant local vaccine expertise. High income countries also 
noted the value added, as GACVS gave global interpretation to their local safety findings.
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Several challenges illustrating the complexities of global vaccine safety were also identified. 
First, expert institutions and committees like GACVS are bound to generate their advice 
based on usually limited albeit up to date evidence (primarily observational studies in the 
post-licensure phase) along with expert opinion. When the missing information is essential 
to allow an evidenced-based conclusion, and the risk from delaying a conclusion is low, 
GACVS has on occasion requested more research on the specific vaccine safety issue. 
However as GACVS (and sometimes WHO) does not have a discretionary research budget, 
it is dependent on persuading other stakeholders to do so. For example, when a vaccine 
against epidemic meningococcal meningitis A in sub-Saharan Africa was made available for 
mass campaigns in people aged 1–29 years, data on the safety of the vaccine during 
pregnancy was not available [40,41]. GACVS then made recommendations for monitoring 
of this safety aspect during the mass vaccination roll-out. As well, vaccine safety issues that 
have been under consideration at GACVS may undergo periodical revision as new scientific 
evidence arises. These reviews may be also be in response to requests from other committees 
or from member states.
Second, while GACVS conclusions are based on the best available evidence and expert 
opinion, there is increasing pressure to incorporate accepted systems such as Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) to qualify that 
evidence. This presents challenges when it comes to discussing health hazards [42]. Rating 
the quality of evidence using systematic literature review methods requires resources and 
adaptation to appraise the quality of observational studies from the post-licensure phase. 
However, the effort of GACVS to anticipate the need for information and standardization of 
vaccine safety in post-licensure studies (e.g. malaria and dengue vaccines) can improve its 
ability to use GRADE in its deliberations.
Third, the current limited capacity of most countries and regions to identify and rigorously 
assess scientifically plausible and potentially significant vaccine safety signals in a timely 
manner continues to be a major challenge for the work of GACVS and WHO [43]. Several 
attempts, to develop multi-country networks for vaccine safety monitoring, supported by 
WHO, GACVS and other partners but with limited funding have had only modest success 
due to the variability of capacities and methods used by each participating country [44,45].
Fourth is the issue of transparency and confidentiality. While a technical committee like 
GACVS should make every effort to make its processes public and clear in order to build 
trust, the committee acknowledged that to make the most appropriate and evidence-based 
decisions, GACVS occasionally receives proprietary scientific information that are shared 
confidentially. Access to this type of information requires balancing safeguards to avoid 
breaches on proprietary information with the need for the public and partners to be fully 
informed of the deliberations. The use of innovative tools for decision-making transparency 
could be of help [46–48].
Finally, the target audiences for GACVS's conclusions needs to be better articulated and 
defined. In particular, GACVS does not have a communication strategy toward the general 
public and whether this is best left to the WHO member countries merits further discussion. 
Engagement of the media has been limited but GACVS has yet to define if media is or is not 
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the best conveyor of its conclusions to the public. Similarly, GACVS has not evaluated if 
print communication, the primary method used thus far, or new social and scientific media 
are the best and modern tools for knowledge transfer to its target audiences [49]. The 
relevance of effective communication is exemplified by some safety concerns that appear to 
be resolved at the scientific and policy levels (e.g., the non-specific effects of vaccination, 
adverse effects of thiomersal, whole-cell pertussis vaccines and encephalopathy, HPV 
vaccine and auto-immune diseases) but continue to surface as public concerns. The use of 
consistent and explicit language in all statements would also increase the reliability of 
interpretation of GACVS recommendations and statements by a wider audience.
4. Discussion
GACVS appears to be a valued technical advisory committee for WHO that provides an 
independent assessment of vaccine safety commonly used by SAGE in their vaccine policy 
deliberations and position statements. GACVS is also perceived as a valued mechanism by 
the member states for providing timely independent evidence-based reviews and conclusions 
on current, emerging or foreseeable vaccine safety issues for policy makers, immunization 
program managers and technical advisory committees. With many more vaccines becoming 
available and enhanced AEFI surveillance systems are detecting vaccine safety signals more 
frequently worldwide [50,51]. Safety concerns are a well-recognized, albeit only one of 
many, contributing factors to increasing vaccine hesitancy noted in some communities [52–
54].
High-income countries have found reassurance and a global perspective when GACVS 
arrives at similar conclusions to their own expert national technical immunization advisory 
committees. However, most LMICs lack (and are unlikely to acquire in the near future) the 
capacity to adequately assess the validity of vaccine safety concerns, therefore they will 
likely continue to rely on GACVS to provide efficient, timely and clear recommendations to 
address such safety worries and misinformation. In the medium term, the development of 
regional safety advisory committees, as well as the enhancement of vaccine safety capacity 
in countries, as outlined in the Global Vaccine Safety Blueprint [36], could extend the reach 
and improve participation in vaccine safety surveillance and decision making.
While GACVS has not had a direct role in building vaccine safety capacity globally 
previously, advocating for its successful deployment in the future could improve detection, 
investigation and causality evaluation of vaccine safety concerns, and strengthen both a 
country and GACVS's position to provide more evidence-based conclusions. Unfortunately, 
despite GACVS recommendations for enhanced post-marketing vaccine safety data to be 
generated in LMICs when new vaccines are being introduced, the necessary long-term 
funding remains insufficient. For example it took more than two decades to document the 
risk of disseminated BCG disease in HIV-infected infants. The deployment of new 
generation rotavirus vaccines in populations from LMICs also required a significant effort 
from public health organizations and manufacturers to document the low risk of 
intussusception related to these vaccines and recommendation for its continued use after a 
careful benefit-risk analysis. Furthermore, there remains a paucity of information on vaccine 
safety for special subgroups such as pregnant women, the elderly, those who are 
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immunocompromised or with chronic disabilities, as vaccine pharmacovigilance systems 
have not focused on these populations and/or have not been well studied during vaccine 
clinical development [55].
From this review, there is evidence that recommendations from GACVS have been helpful 
for vaccine policy decision making at global and country levels but there are limitations to 
these findings. Measuring GACVS impact, as was attempted here, does have several 
limitations. The use of Google Scholar Citation Index as an indirect measure of scientific 
use places high weight on the citation counts and words included in a document's title, and 
does not account for how its reports generated additional inquiries for evidence. 
Furthermore, all recommendations were treated equally, while at the level of vaccine policy 
or science, the prioritization of vaccine safety issues is driven by country, public or scholar 
interest as well as current vaccine context.
Some of the lessons learned from the GACVS 15-year tenure include: (a) its independent 
expertise to provide vaccine safety assessments to the vaccine decision and policy makers; 
(b) its active role in the development of tools, methods and best practices useful for vaccine 
safety assessment; and (c) its increasing inclusion of experts from LMIC to incorporate a 
diversity perspective to its deliberations. As regulators and immunization programs develop 
increased capacity in many countries, including LMIC, additional guidelines and innovative 
methods (eHealth platforms) to perform local post-licensure safety studies will be needed. 
Systems to share their surveillance information using standardized case definitions and 
methods could be crucial for policy decision making. In the meantime and until more 
relevant information becomes available, if the vaccine safety issue of concern requires 
urgent guidance, GACVS cautionary reports will continue to explain the limitations of the 
conclusion with: (1) a statement of relevance of the incomplete information; (2) a summary 
of existing relevant scientific evidence; and (3) the committee's evaluation of possible 
impacts based upon theoretical approaches or research methods generally accepted in the 
scientific community.
GACVS and WHO should continue to encourage regional committees and technical 
advisory groups to address local concerns and to ensure a bidirectional exchange of evidence 
and recommendations specific to local contexts. The observation by the experts that 
variability of the language across GACVS recommendations and statements may preclude 
their interpretation for adoption by users suggests that more standardized wording and 
GRADE assessments to depict the strength of the evidence and expert opinion guided to 
action might be helpful. The small survey of national regulators showed their lack of 
awareness of the conclusions of GACVS. Therefore, to increase GACVS's effectiveness, a 
knowledge transfer strategy that targets and reaches audiences with GACVS's 
recommendations needs to be in a format that can be understood and that can be applied to 
local policies and programs. If its findings and recommendations are to have an impact at 
country level, communication must also be conveyed to policy-makers. The recently created 
NITAG resource center [56] or the vaccine safety toolkit [57] illustrates these innovative 
support channels.
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Finally, given the large gaps in capacity to handle vaccine safety signals in a timely manner 
in many countries worldwide and the resources needed to implement the Global Vaccine 
Safety Initiative (GVSI), GACVS can play an important advocacy role to help fill these 
gaps.
5. Conclusions
Technical advisory committees like GACVS may be able to strengthen the policy-making 
processes of WHO member states by providing in country decision-makers with rigorous 
scientific evaluation of safety issues. GACVS has had an impact on some vaccine safety 
topics within WHO member countries and continues to contribute to vaccine 
recommendations developed by SAGE. Public dissemination of GACVS work deserves 
additional attention and should, ideally, be further developed in collaboration with WHO 
member states. GACVS should also serve as a facilitator to bridge the major gaps in vaccine 
safety capacity globally.
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